IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections - Episode 3
Microbiology Lab Readiness and Education in AMR Care
Early collaboration with microbiology laboratories, reflex testing algorithms, and mechanism-based teaching help ensure that new antimicrobials reach the right patients and that resistance results are interpreted correctly.
New antimicrobials help patients only when laboratories can test them and clinicians understand what the results mean, so implementation depends on partnerships with microbiology and on thoughtful education. Dr. Tamma recalls how delays in susceptibility testing slowed uptake of earlier agents and asks Dr. Shields how hospitals should prepare their laboratories for drugs such as cefepime-zidebactam.
Dr. Shields frames the conversation as a balance of clinical priority, laboratory capacity, and testing accuracy. Because automated panels have limited space, many new agents require add-on gradient strips or disks. He notes encouraging trends, including testing devices that now become available before or alongside drug launch and standardized isolate banks from public health agencies that simplify verification.
He advocates reflex testing algorithms, such as automatically setting up sulbactam-durlobactam testing when CRAB grows in a blood culture, rather than waiting for a clinician request. Dr. Shields also expresses sympathy for overstretched laboratories and suggests that leading with a clear clinical need is the most effective way to secure their collaboration.
Dr. Tamma then asks Dr. Haidar how infectious diseases specialists should communicate resistance mechanisms to colleagues. Dr. Haidar argues that trainees should learn to ask how an organism became resistant before choosing a drug, contrasting a pan-resistant E. coli, likely a KPC producer in his region, with a pan-resistant Pseudomonas, whose resistance has no single explanation. He also cautions against conflating ceftolozane-tazobactam and ceftazidime-avibactam. Dr. Tamma adds that local algorithms and stewardship approval can guide non-specialists who cannot track every detail.
The episode underscores that laboratory readiness and mechanism-based reasoning together determine whether new agents reach the right patients.
The series concludes with "Stewardship and Empiric Therapy in AMR Gram-Negative Infections," as Dr. Shields and Dr. Pogue reframe what stewardship should accomplish.
